The "Improving Access to Audiology Services in England", document in March 2007 by stated that: "Improving Access to Audiology Services in England sets out a simple aspiration: for local health systems to transform the experience of the audiology service for all their patients. This requires a radical reduction in waiting... Complete news at...
Saturday, May 16, 2009
Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment In Alzheimer's Disease And Schizophrenia
Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment In Alzheimer's Disease And Schizophrenia
Synosia Therapeutics announced today that it has started a Phase I clinical trial of SYN-120, its new generation 5-HT6 antagonist under development for the treatment of cognitive impairment associated with Alzheimer's and schizophrenia. The study will assess the safety and tolerability of single ascending doses of SYN-120 in healthy volunteers.
Synosia Therapeutics announced today that it has started a Phase I clinical trial of SYN-120, its new generation 5-HT6 antagonist under development for the treatment of cognitive impairment associated with Alzheimer's and schizophrenia. The study will assess the safety and tolerability of single ascending doses of SYN-120 in healthy volunteers.
Subscribe to:
Posts (Atom)
